Sanofi (NYSE:SNY)‘s stock had its “neutral” rating restated by investment analysts at J P Morgan Chase & Co in a report released on Thursday.

A number of other analysts have also recently weighed in on SNY. upgraded shares of Sanofi from a “reduce” rating to a “hold” rating in a research note on Wednesday, August 30th. Argus reiterated a “buy” rating and set a $55.00 price target on shares of Sanofi in a research note on Friday, September 1st. Zacks Investment Research cut shares of Sanofi from a “hold” rating to a “strong sell” rating in a research note on Friday, October 6th. Barclays upgraded shares of Sanofi from an “underweight” rating to an “equal weight” rating in a research note on Wednesday, November 15th. Finally, Morgan Stanley cut shares of Sanofi from an “overweight” rating to an “underweight” rating in a research note on Friday, December 1st. Two research analysts have rated the stock with a sell rating, nine have issued a hold rating and three have assigned a buy rating to the stock. The stock has a consensus rating of “Hold” and a consensus price target of $53.50.

Shares of Sanofi (NYSE SNY) traded down $0.83 during trading hours on Thursday, reaching $43.09. 2,169,232 shares of the company were exchanged, compared to its average volume of 1,497,251. The firm has a market cap of $110,700.00, a PE ratio of 13.87, a P/E/G ratio of 2.61 and a beta of 0.86. The company has a debt-to-equity ratio of 0.26, a quick ratio of 1.16 and a current ratio of 1.59. Sanofi has a 12-month low of $38.45 and a 12-month high of $50.65.

Hedge funds have recently added to or reduced their stakes in the company. Fisher Asset Management LLC lifted its stake in shares of Sanofi by 3.3% in the 3rd quarter. Fisher Asset Management LLC now owns 14,082,257 shares of the company’s stock worth $701,156,000 after acquiring an additional 443,799 shares during the period. Assetmark Inc. lifted its stake in shares of Sanofi by 34.4% in the 3rd quarter. Assetmark Inc. now owns 158,305 shares of the company’s stock worth $7,882,000 after acquiring an additional 40,484 shares during the period. AMG National Trust Bank lifted its stake in shares of Sanofi by 5.3% in the 2nd quarter. AMG National Trust Bank now owns 51,423 shares of the company’s stock worth $2,464,000 after acquiring an additional 2,594 shares during the period. Alethea Capital Management LLC acquired a new stake in shares of Sanofi in the 3rd quarter worth $794,000. Finally, Argent Trust Co lifted its stake in shares of Sanofi by 32.0% in the 3rd quarter. Argent Trust Co now owns 10,841 shares of the company’s stock worth $540,000 after acquiring an additional 2,629 shares during the period. Institutional investors own 9.09% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “Sanofi (SNY) Rating Reiterated by J P Morgan Chase & Co” was originally posted by American Banking News and is the sole property of of American Banking News. If you are accessing this story on another domain, it was illegally copied and republished in violation of US & international copyright & trademark legislation. The legal version of this story can be accessed at https://www.americanbankingnews.com/2017/12/14/sanofi-sny-rating-reiterated-by-j-p-morgan-chase-co.html.

Sanofi Company Profile

Sanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. The Company’s segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including Speciality Care (Rare Diseases, Multiple Sclerosis, and Oncology), Diabetes and Cardiovascular, Established Prescription Products, Consumer Healthcare and Generics, and research and development, production and marketing activities for all of the Company’s pharmaceuticals operations.

Analyst Recommendations for Sanofi (NYSE:SNY)

Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.